Surgical management of complications after transcatheter closure of an atrial septal defect or patent foramen ovale  by Berdat, Pascal A. et al.
closure, which remains the gold standard. Especially
the problems encountered after failed transcatheter clo-
sure have to be analyzed in detail.
Only by taking into consideration both the results of
attempted transcatheter closure and the results of surgi-
cal correction after failed or complicated transcatheter
closure can the risks of this procedure be fully evaluat-
ed. We report early and late outcome of 10 (8%) of 124
patients who underwent percutaneous closure of an
ASD or PFO and who subsequently required surgical
treatment of either cardiac or vascular complications
related to the device insertion.
Methods
Patient characteristics. Between April 1994 and March
1999, 124 patients (48 with ASD and 76 with PFO) underwent
percutaneous closure of their defect at our institution by use of a
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Sideris buttoned device (Custom Medical Devices, Amarillo,
Tex) in 52, Amplatzer Septal Occluder (AGA Medical Corp,
Golden Valley, Minn) in 28, and others (CardioSEAL Septal
Occluder, Nitinol Medical Technology, Inc, Boston, Mass;
PFO-Star, Applied Biometrics Inc, Burnsville, Minn; DAS,
AngelWings Occluder, Microvent Corp, White-Bear Lake,
Minn) in 38 patients. Complications requiring either cardiac or
vascular operations occurred in 10 patients. Demographic data
are shown in Table I. The mean age at operation was 45 ± 18
years (range, 4-70 years). An ostium secundum ASD was pre-
sent in 7 patients, with a mean diameter of 25 ± 6 mm (range,
15-31 mm) and a mean left-to-right shunt of 2.8 ± 1.0 (range,
1.3-4.3). A PFO with a grade 3 right-to-left shunt (passage of >
25 bubbles demonstrated by transesophageal echocardiography
with bubble contrast enhancement) was present in 3 patients and
was diagnosed after a stroke presumed to be caused by para-
doxic embolization. The shunt was unchanged in 8 patients (Fig
1) and estimated to be reduced but still significant in 1 patient
after an attempt at transcatheter closure. Seven Sideris buttoned
devices were used in 6 patients, and 4 Amplatzer devices were
used in 3 patients. In the 1 remaining patient, the procedure had
to be aborted before a device could be placed because of limb
ischemia after initial puncture of the femoral artery.
Patients underwent echocardiography before and the day
after the catheter intervention. Echocardiographic results are
summarized in Table I. The left ventricular (LV) ejection frac-
tion was normal in all patients (72% ± 5%; range, 65%-83%).
Right ventricular dilation was present in 7 patients, and addi-
tional right atrial dilation was present in 6 patients.
Pulmonary arterial hypertension was present in 6 patients.
Severe mitral regurgitation was present in 1 patient, and mild
regurgitation was present in another.
Follow-up. Data from the latest follow-up period were col-
lected from physical examinations performed recently or
telephone interviews, as well as from echocardiography and
work done in the vascular laboratory.
Statistics. Data are expressed as absolute values, percent-
ages, or mean ± SD where appropriate.
Results
Operations. Surgical data are presented in Table II.
The mean time interval between implantation of the
device and surgical treatment was 155 ± 230 days
Fig 1. Preoperative echocardiography showing a malpositioned Sideris buttoned device and a significant residual
left-to-right shunt through the ASD.
Table I. Baseline data in 10 patients
Mean ± SD Range
Age (y) 45 ± 18 4-70
BSA (m2) 1.7 ± 0.4 0.7-2
M/F 3:7
ASD/PFO (patients) 7:3
ASD diameter (mm) 25 ± 6 15-31
Shunt after device implantation
Unchanged 7*
Relevant 1
Minimal 2
LV ejection fraction (%) 72 ± 5 65-83
RV dilatation (patients) 7
RA dilatation (patients) 6
Pulmonary arterial hypertension (patients) 6†
Mitral regurgitation (patients) 2
BSA, Body surface area; RV, right ventricular; RA, right atrial.
*Including 1 patient in whom no device could be placed.
†Data not available in 2 patients.
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(range, 0-748 days). There were 13 operations per-
formed in 10 patients, and the ASD or PFO was sur-
gically closed in 8 patients. Indications for surgical
closure of the ASD or PFO were persistent left-to-
right shunt caused by malposition or dislocation of
the device (7 patients) or preliminary puncture site
complication preventing application of a device (1
patient). In 4 patients a polytetrafluoroethylene patch*
was needed because the firmly healed device had to
be cut out with additional resection of atrial septal tis-
sue. If present, the device was always removed (7
patients, Fig 2). In 1 patient no device had previously
been placed interventionally because of injury of the
femoral artery and consecutive acute leg ischemia at
the start of the procedure. Additionally, mitral valve
replacement was done in 1 patient with pre-existent
severe mitral regurgitation. In a 70-year-old patient
with LV perforation, the operation included closure of
the LV and two re-explorations because of persistent
bleeding.
In 2 patients iliac or femoral artery injury with con-
secutive leg ischemia in 1 was treated by reconstruction
of the vessel; the second treatment included evacuation
of a large retroperitoneal hematoma.
In 1 patient percutaneous retrieval of the dislocated
device was successful down to the iliac vein, from
where it was extracted surgically to avoid local injury.
In 4 patients surgery had to be performed urgently: in
2 patients as a result of iliac or femoral artery injury, in
1 patient with pericardial tamponade as a result of LV
perforation, and in 1 patient with the device stuck in the
iliac vein.
Mean operation time was 167 ± 140 minutes (range,
55-540 minutes), cardiopulmonary bypass time was 53 ±
72 minutes (range, 0-256 minutes), and duration of aortic
crossclamping was 20 ± 16 minutes (range, 0-44 min-
utes). Transfusion of blood components was necessary in
5 patients, and the mean number of units of blood com-
ponents transfused was 5 ± 13 (range, 0-44 units).
Duration of stay in the intensive care unit was 2 ± 1
days (range, 0-3 days), and mean total hospital stay,
including hospital stay for interventional and surgical
treatment, was 12 ± 5 days (range, 4-20 days). Mean
hospital stay for surgical treatment alone was 9 ± 4
days (range, 2-15 days).
Mortality. There was one cardiac-related death.
Dislocation of the Sideris device into the ventricle
occurred in a 70-year-old patient during percutaneous
closure of a 27-mm ASD. Attempts to retrieve the
device led to LV perforation with immediate pericar-
dial tamponade. Although emergency surgical inter-
vention was performed, the laceration of the left ven-
tricle could not be treated successfully, and the patient
died after 2 re-explorations because of persistent bleed-
ing caused by a coagulation disorder and, ultimately,
electromechanical dissociation on the third day.
Morbidity. There was no relevant perioperative or
postoperative morbidity after surgical closure of an
ASD or vascular intervention. Two patients had tran-
sient low cardiac output, with 1 of them having a tran-
sient episode of atrial fibrillation. No perioperative
cerebral vascular event, bleeding, or recurrent vascular
complication occurred. All patients recovered well
from surgery and were in functional New York Heart
Association class I to II at discharge.
Follow-up. The late outcome of all survivors was
good. Mean follow-up time was 698 ± 543 days (range,
Fig 2. A, B, Intraoperative right atrial view with malpositioned Sideris buttoned devices in situ. Picture of the same
patient as seen in Fig 1.
A B
*W. L. Gore & Associates, Inc, Flagstaff, Ariz.
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62-1505 days). No patient died during follow-up. Two
patients had mild persistent dyspnea of New York Heart
Association class II, and 2 others had palpitations, 1
with mild exercise intolerance. One patient had a
painful scar 2 months after vascular surgery and anoth-
er had dysesthesia of the leg. Oral anticoagulants were
used by 4 patients, aspirin by 1, β-blockers by 2, amio-
darone by 1, and diuretics by 1. Echocardiographic
controls were done in 5 of the 7 surviving patients after
cardiac surgery and showed normalization of the car-
diac chamber dimensions in 4 patients and normal LV
systolic function and no residual shunt in all patients.
Vascular examination showed normal peripheral circu-
lation in all 3 patients after vascular procedures. There
were no cardiac- or vascular-related readmissions.
Discussion
During recent years, transcatheter closure has
become an alternative to an operation for the treatment
of ostium secundum ASD and PFO.1-4 This new
method, however, has to be compared with an opera-
tion, which remains the gold standard for the treatment
of ASD.
Reports that specifically evaluate the outcome of
patients after an operation for failed transcatheter clo-
sure are rare.5-9 Therefore more information is needed
concerning this subgroup of patients.
Once the indication for closure of an ASD or a PFO
is made, the goal of treatment should be a definitive
repair. Treatment aims at restitution of normal cardiac
anatomy and function, elimination of potential compli-
cations, normalization of life expectancy, and elimina-
tion of a requirement for life-long drug therapy.
Surgical repair meets these basic requirements and
offers reliable and excellent results because closure of
an ASD and a PFO can today be done with a mortality
rate below 1%10-12—in recent series even with zero
mortality in any patient group13-18—and an overall
morbidity rate between 2.5%10 and 13%,11 with a low
probability of residual shunt below 2%.11,14 Further
surgical improvements of recent years include a less-
invasive approach through smaller incisions,13-18
improved perfusion techniques, application of fast-
track anesthetic protocols, reduction of hospital
stay,16,17 and reduction of costs. Nevertheless, inherent
disadvantages of surgical repair remain, such as the
incision, morbidity of cardiopulmonary bypass, post-
operative arrhythmias, longer hospital stay, and inabil-
ity to work for 2 to 4 weeks. From the transcatheter
approach, one would expect a very low periprocedural
risk, a short learning curve, permanent good results,
and a good cost-to-time effectiveness. However, trans-
catheter procedures are not free of potential complica-
tions, such as recurrent cerebral embolism,19 cardiac
perforation leading to tamponade,6,15 device malposi-
tion or embolization in 4% to 20%,8,20-25 residual shunt
in up to 30%,6,20,26 vascular trauma,22,26 thrombus for-
mation on the device,6,20 or induced mitral regurgita-
tion.8 Considering the present results, an operation
after failed or complicated transcatheter closure seems
still to be as effective as primary surgical closure
because no significant complication occurred after
Table II. Surgical data in 10 patients
Mean ± SD Range
Time interval to operation (d) 155 ± 230 0-748
Operation time (min) 167 ± 140 55-540
CPB time (min) 53 ± 72 0-256
Aortic crossclamp time (min) 20 ± 16 0-44
ASD (pc:dc) 4 (2:2)
ASD pc + MVR 1
ASD dc + LV suture 1
ASD total 6
PFO pc 1
PFO dc + femoral artery reconstruction + evacuation of
retroperitoneal hematoma 1
PFO total 2
Iliac vessel reconstruction 1
Device extraction iliac vein 1
Transfusion (units) 5 ± 13 0-44
ICU stay (d) 2 ± 1 0-3
Surgical hospital stay (d) 9 ± 4 2-15
Hospital stay (d) 12 ± 5 4-20
CPB, Cardiopulmonary bypass; pc, patch closure; dc, direct closure; ICU, intensive care unit; MVR, mitral valve replacement.
ASD or PFO closure, and late outcome is excellent.
However, one death occurred in this group as a result of
LV perforation after failed transcatheter attempts to
retrieve a large embolized ASD closure device. Despite
emergency operation, the elderly patient died of diffuse
persistent bleeding and low cardiac output. Perforation
of cardiac or central vascular structures are rarely
reported6,20,21,26 but mostly require surgical interven-
tion. This case shows that potentially fatal complica-
tions may occur during transcatheter closure, which
may not be correctable by means of an emergency
operation. However, mortality after the transcatheter
approach is low, with most authors reporting no mor-
tality in their series.3,20,26-28
In the present report the most frequent indication for
surgery (80%) was device malposition or embolism,
occurring in 8 (6.5%) of 124 patients. This might be
due to the large diameter of 25 ± 6 mm of ASDs in this
group. In the literature, device dislocation or embolism
is the most frequently reported complication of trans-
catheter closure, with rates ranging from 4%22 to 21%24
and necessity for surgery in approximately 70% to
100% of those cases.4,22-25,27 The dislocation rate is
mainly dependent on the device used, with the ASDOS
(∅sypka Corporation, Rheinfelden, Germany) and
Sideris devices having the highest failure rates.6,7,21,23-25
The Amplatzer device shows more promising results.
The anatomic features of the ASD (ie, size and quality
of the rim) are also of importance.
The second most frequent indication (30%) for an
operation in our series was a vascular injury at the
puncture site. In the literature complications of the
puncture site requiring vascular surgery seem to be
rare, with Latson and associates22 reporting 0.5% and
Sievert and associates26 reporting 3.4%, which is con-
sistent with our results of 2.4%.
Additional indications for operation were thrombus
formation on the device in one patient, recurrent tran-
sient ischemic attacks in another patient,19 and mild
mitral regurgitation in a third patient.
All those operations were done without further com-
plications, and late follow-up was excellent, with all
patients in functional class I or II. Therefore, our results
are comparable with those after primary surgical clo-
sure of an ASD or PFO.
In summary, an ASD and PFO can successfully be
closed surgically, and the device can be extracted after
failed transcatheter closure, with excellent results and
low morbidity. However, in cases with serious compli-
cations, such as cardiac perforation, there is a fatal risk.
Intracardiac dislocation or embolization of the device
and complications of the femoral or iliac vessels are the
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most frequent problems leading to surgical interven-
tions. Failed or complicated transcatheter closure of an
ASD or PFO, occurring in up to 10% of patients, con-
siderably raises the costs of this procedure by length-
ening of both intensive care and hospital stay, need for
additional operations, and need for blood transfusion.
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